Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
Sponsor: Geneplus-Beijing Co. Ltd.
Summary
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of mutations and therapy response; whether ctDNA detection can be used to predict the risk of ovarian cancer recurrence; and the characteristics of immune repertoire before and after treatment in patients with ovarian cancer.
Key Details
Gender
FEMALE
Age Range
18 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
104
Start Date
2017-11-25
Completion Date
2024-12
Last Updated
2024-07-18
Healthy Volunteers
No
Conditions
Locations (6)
Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
Peking Union Medical College Hospital
Beijing, China
Peking University International Hospital
Beijing, China